It has been indicated that the loss of ZO-2 participates in the processes involving epithelial-mesenchymal transition (EMT), diffusely infiltrating growth, and ultimately frequent metastatic spread of GC cells (Shinto et al., 2010), which is consistent with our observations that declined ZO-2 levels were correlated with poor survival rate in GC patients (Supplementary Figures 3A–C). Here, TJP2 is linked to gastric cancer.